Show simple item record

dc.contributor.authorGilabert-Juan, Javier
dc.contributor.authorLópez-Campos, Guillermo
dc.contributor.authorSebastiá-Ortega, Noelia
dc.contributor.authorGuara-Ciurana, Sonia
dc.contributor.authorRuso Julve, Fulgencio
dc.contributor.authorPrieto, Carlos
dc.contributor.authorCrespo Facorro, Benedicto 
dc.contributor.authorSanjuán, Julio
dc.contributor.authorMoltó, María Dolores
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2019-08-01T16:31:40Z
dc.date.issued2019-08
dc.identifier.issn0889-1591
dc.identifier.issn1090-2139
dc.identifier.urihttp://hdl.handle.net/10902/16654
dc.description.abstractBackground During last years, there has been an intensive search for blood biomarkers in schizophrenia to assist in diagnosis, prognosis and clinical management of the disease. Methods In this study, we first conducted a weighted gene coexpression network analysis to address differentially expressed genes in peripheral blood from patients with chronic schizophrenia (n?=?30) and healthy controls (n?=?15). The discriminating performance of the candidate genes was further tested in an independent cohort of patients with first-episode schizophrenia (n?=?124) and healthy controls (n?=?54), and in postmortem brain samples (cingulate and prefrontal cortices) from patients with schizophrenia (n?=?34) and healthy controls (n?=?35). Results The expression of the Eukaryotic Translation Initiation Factor 2D (EIF2D) gene, which is involved in protein synthesis regulation, was increased in the chronic patients of schizophrenia. On the contrary, the expression of the Thymocyte Selection-Associated High Mobility Group Box (TOX) gene, involved in immune function, was reduced. EIF2D expression was also altered in first-episode schizophrenia patients, but showing reduced levels. Any of the postmortem brain areas studied did not show differences of expression of both genes. Conclusions EIF2D and TOX are putative blood markers of chronic patients of schizophrenia, which expression change from the onset to the chronic disease, unraveling new biological pathways that can be used for the development of new intervention strategies in the diagnosis and prognosis of schizophrenia disease.es_ES
dc.description.sponsorshipAcknowledgments: This work was supported by Fondo de Investigación Sanitaria, Ministerio de Economía y Competitividad, Spain (PI10/01399, PI13/00447; PI17/00402, co-financed by FEDER) to J. Sanjuan and M.D. Moltó; Generalitat Valenciana PROMETEO Excellence Program, Spain (PROMETEO2016/082) to J Sanjuán. J Gilabert-Juan and N. Sebastiá-Ortega were recipients of research contracts from CIBERSAM, Spain. The RNA samples donated bythe Stanley Medical Research Institute Brain Collection were courtesy of Drs. Michael B. Knable, E. Fuller Torrey, Maree J. Webster, and Robert H. Yolken. The authors also thank the collaboration of the staff members of the hospitals.es_ES
dc.format.extent7 p.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rights© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceBrain, Behavior, and Immunity Volume 80, August 2019, Pages 909-915es_ES
dc.titleTime dependent expression of the blood biomarkers EIF2D and TOX in patients with schizophreniaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.bbi.2019.05.015es_ES
dc.rights.accessRightsembargoedAccesses_ES
dc.identifier.DOI10.1016/j.bbi.2019.05.015
dc.type.versionacceptedVersiones_ES
dc.date.embargoEndDate2020-08-01


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 licenseExcept where otherwise noted, this item's license is described as © 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license